Morgan Galliart
Physician Assistant · Russell, KSNPI 1427533967
Payments from drug & device makers
Across 96 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$256
- AbbVie$236
- Sunovion Pharmaceuticals Inc.$149
- Sumitomo Pharma America, Inc.$129
- Lilly USA, LLC$126
- Mylan Specialty L.p.$104
- plus $683 from 14 others
What the payments were for
- Food & beverage$1,683100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $256 |
| AbbVie | 13 | $236 |
| Sunovion Pharmaceuticals Inc. | 8 | $149 |
| Sumitomo Pharma America, Inc. | 6 | $129 |
| Lilly USA, LLC | 8 | $126 |
| Mylan Specialty L.p. | 6 | $104 |
| Dexcom, Inc. | 5 | $97 |
| Novartis | 4 | $89 |
| Insulet Corporation | 3 | $77 |
| AstraZeneca | 5 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| Johnson & Johnson | 3 | $52 |
| Boehringer Ingelheim | 3 | $49 |
| Electromed, Inc. | 3 | $42 |
| Novo Nordisk | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 3 | $30 |
| Genentech USA, Inc. | 2 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
How this compares
$1,683 in reported general payments places this provider in the 75th percentile of 1,016 physician assistant providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 48 | $48,968 |
| EliquisApixaban | 54 | $34,473 |
| TrulicityDulaglutide | 24 | $30,942 |
| FarxigaDapagliflozin Propanediol | 27 | $21,941 |
| JardianceEmpagliflozin | 34 | $21,276 |
| XareltoRivaroxaban | 25 | $20,961 |
| OzempicSemaglutide | 12 | $13,249 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $11,883 |
| Advair HfaFluticasone Propion/Salmeterol | 24 | $9,196 |
| Mesalamine | 14 | $8,325 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $4,967 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 20 | $3,731 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $3,555 |
| Levothyroxine Sodium | 303 | $2,268 |
| Atorvastatin Calcium | 276 | $1,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $126 | $79,90972 claims |
| AstraZenecaFarxiga | $75 | $21,94127 claims |
| Boehringer IngelheimJardiance | $49 | $21,27634 claims |
| Johnson & JohnsonXarelto | $52 | $20,96125 claims |
| Novo NordiskOzempic | $32 | $13,24912 claims |
| AbbVieSynthroid | $236 | $1,36338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,016 physician assistant providers in Kansas.
Other physician assistant in Russell
- Sierra FergusonWichita$25K
- Dylan TimmermannTopeka$19K
- Heather HowellKansas City$16K
- Amy BrettmanShawnee$14K
- Ashton YoungersWichita$14K
- Anthony GunawanLakin$13K
- Therese SchrandtWichita$13K
- Mike HallWichita$13K
- Melissa WilkesFort Riley$13K
- Jenny MartensWichita$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.